Allogene Therapeutics Inc [ALLO] stock prices are down -0.52% to $1.93 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ALLO shares have gain 6.04% over the last week, with a monthly amount drifted -1.03%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on May 31, 2024, and set its price target to $11. On January 05, 2024, downgrade downgraded it’s rating to Mkt Perform. Guggenheim downgraded its rating to a Neutral. Citigroup initiated its recommendation with a Buy and recommended $7 as its price target on December 08, 2023.
The stock price of Allogene Therapeutics Inc [ALLO] has been fluctuating between $1.78 and $5.78 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $1.93 at the most recent close of the market. An investor can expect a potential return of 1402.59% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
The Allogene Therapeutics Inc [NASDAQ:ALLO] reported sales of 0.04M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -1437.6% with Operating Profit Margin at -6501.95%, Pretax Profit Margin comes in at -6591.37%, and Net Profit Margin reading is -6591.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.58 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8733 points at the first support level, and at 1.8167 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0133, and for the 2nd resistance point, it is at 2.0967.
Ratios To Look Out For
It’s worth pointing out that Allogene Therapeutics Inc [NASDAQ:ALLO]’s Current Ratio is 9.35. On the other hand, the Quick Ratio is 9.35, and the Cash Ratio is 1.57. Considering the valuation of this stock, the price to sales ratio is 10116.58, the price to book ratio is 0.87.
Transactions by insiders
Recent insider trading involved Roberts Zachary, EVP of R&D, that happened on Jan 21 ’25 when 27199.0 shares were sold. Officer, Roberts Zachary completed a deal on Jan 21 ’25 to buy 27199.0 shares. Meanwhile, Director MESSEMER DEBORAH M. sold 9136.0 shares on Dec 09 ’24.
